Figg WD - Search Results

1

Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines.

Blagosklonny MV, Dixon SC, Robey R, Figg WD. Blagosklonny MV, et al. Among authors: figg wd. Int J Oncol. 2001 Apr;18(4):697-704. doi: 10.3892/ijo.18.4.697. Int J Oncol. 2001. PMID: 11251163

2

Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target.

Dixon SC, Soriano BJ, Lush RM, Borner MM, Figg WD. Dixon SC, et al. Among authors: figg wd. Ann Pharmacother. 1997 Jan;31(1):76-82. doi: 10.1177/106002809703100113. Ann Pharmacother. 1997. PMID: 8997471 Review.

3

In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3.

Dixon SC, Zalles A, Giordano C, Lush RM, Venzon D, Reed E, Figg WD. Dixon SC, et al. Among authors: figg wd. Cancer Lett. 1997 Feb 26;113(1-2):111-6. doi: 10.1016/s0304-3835(97)04603-x. Cancer Lett. 1997. PMID: 9065809

4

Methods for extracting and amplifying genomic DNA isolated from frozen serum.

Dixon SC, Horti J, Guo Y, Reed E, Figg WD. Dixon SC, et al. Among authors: figg wd. Nat Biotechnol. 1998 Jan;16(1):91-4. doi: 10.1038/nbt0198-91. Nat Biotechnol. 1998. PMID: 9447601 No abstract available.

5

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent.

Bauer KS, Dixon SC, Figg WD. Bauer KS, et al. Among authors: figg wd. Biochem Pharmacol. 1998 Jun 1;55(11):1827-34. doi: 10.1016/s0006-2952(98)00046-x. Biochem Pharmacol. 1998. PMID: 9714301

6

Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models.

Sausville EA, Lush RD, Headlee D, Smith AC, Figg WD, Arbuck SG, Senderowicz AM, Fuse E, Tanii H, Kuwabara T, Kobayashi S. Sausville EA, et al. Among authors: figg wd. Cancer Chemother Pharmacol. 1998;42 Suppl:S54-9. doi: 10.1007/s002800051080. Cancer Chemother Pharmacol. 1998. PMID: 9750030 Clinical Trial.

7

Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor.

Horti J, Dixon SC, Logothetis CJ, Guo Y, Reed E, Figg WD. Horti J, et al. Among authors: figg wd. Br J Cancer. 1999 Mar;79(9-10):1588-93. doi: 10.1038/sj.bjc.6690253. Br J Cancer. 1999. PMID: 10188911 Free PMC article.

8

Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells.

Dixon SC, Kruger EA, Bauer KS, Figg WD. Dixon SC, et al. Among authors: figg wd. Cancer Chemother Pharmacol. 1999;43 Suppl:S78-84. doi: 10.1007/s002800051103. Cancer Chemother Pharmacol. 1999. PMID: 10357564

9

The androgen receptor: genetic considerations in the development and treatment of prostate cancer.

Cude KJ, Dixon SC, Guo Y, Lisella J, Figg WD. Cude KJ, et al. Among authors: figg wd. J Mol Med (Berl). 1999 May;77(5):419-26. doi: 10.1007/s001090050372. J Mol Med (Berl). 1999. PMID: 10426191 Review.

10

Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.

Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, Figg WD. Small EJ, et al. Among authors: figg wd. Clin Cancer Res. 1999 Jul;5(7):1738-44. Clin Cancer Res. 1999. PMID: 10430077 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

793 results

Search Page

Filters